Kura Oncology, Inc. (KURA)
| Market Cap | 700.65M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -197.55M |
| Shares Out | 77.76M |
| EPS (ttm) | -2.36 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,995,558 |
| Open | 8.92 |
| Previous Close | 8.97 |
| Day's Range | 8.88 - 9.17 |
| 52-Week Range | 8.85 - 24.17 |
| Beta | 0.76 |
| Analysts | Strong Buy |
| Price Target | 30.13 (+234.41%) |
| Earnings Date | Nov 7, 2024 |
About KURA
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpeli... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for KURA stock is "Strong Buy." The 12-month stock price forecast is $30.13, which is an increase of 234.41% from the latest price.
News
Kura Oncology Presents Deep Value At Today's Prices (Rating Upgrade)
Kura Oncology, Inc.'s collaboration with Kyowa Kirin brings $330M upfront and a potential $1.2B in milestone payments, enhancing long-term shareholder value despite initial market disappointment. Zift...
Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting
– Interim analysis from Phase 1a portion of KOMET-007 shows 100% CR rate in NPM1-m and 83% CR rate in KMT2A-r 1L adverse risk AML with 7+3 –
Kura Oncology to Host Virtual Investor Event on December 9, 2024
Live webcast and conference call to discuss presentation of updated data from KOMET-007 combination trial of ziftomenib at ASH Live webcast and conference call to discuss presentation of updated data ...
Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit
SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment ...
Kura Oncology to partner with Kyowa Kirin for blood cancer therapy
Kura Oncology said on Wednesday it will collaborate with Japan's Kyowa Kirin to develop and commercialize the blood cancer therapy ziftomenib.
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
– Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including $420 million in near-term milestone payments and opt-in right for solid tumors –
Kura Oncology, Inc. (KURA) Q3 2024 Earnings Call Transcript
Kura Oncology, Inc. (NASDAQ:KURA) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Pete De Spain - Head, Investor Relations Dr. Troy Wilson - President and CEO Tom Do...
Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting
– Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r adverse risk AML patients selected for oral presentation on Saturday, December 7th –
Kura Oncology to Report Third Quarter 2024 Financial Results
SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment ...
Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cartography Biosciences, Inc., an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the ap...
Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)
– Combination of ziftomenib and imatinib shows robust and durable antitumor activity in imatinib-sensitive (1L) and imatinib-resistant (2L/3L) GIST models –
Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors
– New preclinical data to be presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics – – New preclinical data to be presented at EORTC-NCI-AACR Symposium on Molecular Target...
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology
SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors
SAN DIEGO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Kura Oncology, Inc. (KURA) Q2 2024 Earnings Call Transcript
Kura Oncology, Inc. (NASDAQ:KURA) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Pete De Spain - Head, IR Troy Wilson - President and CEO Thomas Doyle - SVP of Financ...
Kura Oncology Announces FDA Clearance of IND Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors (GIST)
– Preclinical data suggest combination of ziftomenib and imatinib has potential to resensitize patients to imatinib and induce durable responses –
Kura Oncology to Report Second Quarter 2024 Financial Results
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment ...
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, July 05, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines fo...
Kura Oncology Reports Preclinical Data Supporting Potential for Menin Inhibitor in Diabetes
– Ziftomenib induces insulin production, improves insulin sensitivity and reduces insulin resistance in preclinical model of type 2 diabetes –
Life Science Cares San Diego Teams with Kura Oncology to Support Nutritional Needs of the San Diego Community
SAN DIEGO--(BUSINESS WIRE)--Life Science Cares San Diego, a nonprofit organization activating the financial and human capital of the life sciences industry and partnering with local nonprofits to disr...
Kura Oncology to Participate in Jefferies Global Healthcare Conference
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment o...
Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML
– Company enrolls 85 patients with R/R NPM1-mutant AML in fewer than 16 months – – Topline data expected in early 2025 – – Breakthrough Therapy Designation to enable expedited review by FDA – SAN DIEG...
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment o...
Kura Oncology, Inc. (KURA) Q1 2024 Earnings Call Transcript
Kura Oncology, Inc. (NASDAQ:KURA) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Pete De Spain - EVP, IR Troy Wilson - President & CEO Thomas Doyle - SVP of Finance & Ac...
Kura Oncology Reports First Quarter 2024 Financial Results
– Breakthrough Therapy Designation for ziftomenib in NPM1-mutant AML – – Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment by mid-2024 – – Positive prelimina...